Shire plc / Jerini AG

Hereditary Angioedema (HAE)

Disease Overview

Hereditary angioedema (HAE) is a rare genetic disorder caused by C1-esterase inhibitor deficiency that produces unpredictable, painful, and potentially life-threatening episodes of swelling in the skin, abdomen, and airway. Attacks can require emergency intervention, and prior to targeted therapies, treatment options were limited to fresh frozen plasma and supportive care.

Competitive Landscape

At the time of Shire's 2008 acquisition of Jerini, the HAE acute treatment landscape was nearly empty in the US. Cinryze (C1 esterase inhibitor, ViroPharma — later acquired by Shire in 2014) and Berinert (CSL Behring) were the principal C1-INH replacement products in development or early launch, while Kalbitor (ecallantide, Dyax) was advancing as a kallikrein inhibitor. Firazyr (icatibant), a first-in-class bradykinin B2 receptor antagonist, was differentiated by subcutaneous self-administration without IV infusion infrastructure. The European Commission approved Firazyr in July 2008, days after the Shire-Jerini deal was announced, and FDA approval followed in August 2011 after an initial not-approvable letter. The acquisition gave Shire a launch-ready European rare-disease asset that complemented its Human Genetic Therapies franchise (Replagal, Elaprase) and positioned the company to lead a category that has since expanded to include Takhzyro (lanadelumab, Takeda) and Orladeyo (berotralstat, BioCryst). The deal accelerated category creation and entrenched Shire as the dominant HAE commercial player by the early 2010s.